Beacon Biomedical

Beacon Biomedical is a biotechnology company that aims to revolutionize early cancer detection and diagnosis. Established in 2014 and headquartered in the United States, the company's mission is reflected in its slogan: "Easy, Accurate & Affordable Blood Based Screening for early detection of cancer and COVID-19 detection and antibodies." Beacon Biomedical is focused on developing and commercializing CLIA laboratory and point-of-care CLIA waived tests for early cancer detection. Their flagship product, BeScreened™-CRC, is a blood-based test designed for the early detection of colorectal cancer. Notably, their product development pipeline includes assays for the early detection of breast, lung, prostate, and ovarian cancers. Furthermore, the company has positioned itself at the forefront of molecular proteomic diagnostics, catering to the critical need for accessible and precise cancer screening. With its strong emphasis on innovative solutions, Beacon Biomedical represents a promising investment opportunity in the biotechnology and healthcare industries. However, information about their last investment and investors is currently unavailable. In summary, Beacon Biomedical's dedication to making cancer detection easy, accurate, and affordable underscores its potential to bring about substantial advancements in the early detection of cancer. For more information about Beacon Biomedical, visit www.beaconbiomedical.com.